Search results
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
Market Watch· 2 days agoVaccine-related stocks moved sharply higher Wednesday as new human bird-flu cases were reported in...
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks via Yahoo Finance· 1 day agoIn the past six months, shares of MRNA have rallied 108.94%. (See the last biotech stock roundup...
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar...
Zacks· 13 hours agoMay 24, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial ...
Moderna and Pfizer In Talks With U.S. To Make a Bird Flu Vaccine
Barrons.com· 2 days agoThe stock, however, keeps going up. Moderna shares have climbed 20% just this week, and 45% since...
Moderna Inc (MRNA)'s Uncertain Future: Understanding the Barrier
Guru Focus· 4 days agoLong-established in the Biotechnology industry, Moderna Inc (MRNA, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth ...
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Benzinga via Yahoo Finance· 7 days agoModerna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent...
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% By Investing.com
Investing.com· 2 days agoU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51%
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks via Yahoo Finance· 4 days agoAll this pulled up the stock price. The acquisition of Harpoon Therapeutics added its lead pipeline...
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks via Yahoo Finance· 1 day agoImage Source: Zacks Investment Research Descartes-08 is an autologous anti-B cell maturation antigen...
Arcturus Therapeutics’ (ARCT) Outperform Rating Reaffirmed at William Blair
ETF DAILY NEWS· 12 hours agoARCT has been the topic of a number of other research reports. Canaccord Genuity Group lowered their target price on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a buy rating ...